Eob primovist

Manufactured by Bayer

Sourced in Japan

EOB Primovist is a contrast agent used in magnetic resonance imaging (MRI) procedures. It contains the active ingredient gadoxetic acid, which enhances the visibility of certain structures or abnormalities within the body during the MRI scan.

Automatically generated - may contain errors

Lab products found in correlation

Ingenia, by Philips (1 mentions)

Close spelling variants of this product

Gd-EOB-BPTA—Primovist Primovist

5 protocols using eob primovist

Gadoxetic Acid-Enhanced Hepatobiliary MRI Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Magnetic contrast enhancement was obtained by the intravenous administration of 25 μmol/kg of gadoxetic acid (EOB-Primovist, Bayer Yakuhin, Osaka, Japan) injected at a rate of 2.0 ml/s followed by 20 ml of saline delivered at the same rate using a power injector (Sonic Shot 50; Nemoto-Kyorindo, Tokyo, Japan).
Circular- and pseudo-random-hepatobiliary-phase imaging was initiated 20 min after the gadoxetic-acid injection. HBP imaging was with TIGRE with parallel imaging (RAPID) using navigator echo-based respiratory gating technique (section thickness and interval 1.8 mm, slab thickness 216 mm, TR/TE 4.0 ms/1.8 ms, FA 15°, FOV 36 × 27 cm², matrix 332 × 216, parallel imaging factor 3 [2.0 for phase direction and 1.5 for slice direction]). The scanner was the same 3T MRI instrument used in the phantom study. All images were obtained in the transverse plane. Although dynamic MRI scans using gadoxetic acid were obtained for the clinical studies they were not evaluated in this study.

Nakamura Y., Higaki T., Nishihara T., Harada K., Takizawa M., Bito Y., Narita K., Akagi M., Matsubara Y., Kamioka S., Akiyama Y., Iida M, & Awai K. (2019). Pseudo-random Trajectory Scanning Suppresses Motion Artifacts on Gadoxetic Acid-enhanced Hepatobiliary-phase Magnetic Resonance Images. Magnetic Resonance in Medical Sciences, 19(1), 21-28.

+ Open protocol

+ Expand

Liver MRI with Gd-EOB-DTPA in Hypointense Tumors

Check if the same lab product or an alternative is used in the 5 most similar protocols

Our Institutional Review Board approved this retrospective study and waived the requirement for informed consent. Using a computerized search for MRI examinations performed between June 2018 and March 2020 at our institution, 271 consecutive patients who underwent liver MRI with Gd-EOB-DTPA (EOB Primovist; Bayer Yakuhin, Osaka, Japan) including both HR HBP imaging with CS and standard HBP imaging were identified. Among these 271 patients, we excluded patients with no liver tumors showing hypointensity on HBP (n = 123) and patients with hypointense liver tumors on HBP but no final diagnosis confirmed (n = 8). Furthermore, of these 140 patients, 18 patients were excluded due to severe motion or aliasing artifacts (n = 12) and the presence of diffuse liver tumors (n = 6). A total of 122 patients were ultimately included in this study (66 men, 56 women; median age 69 years old; age range, 39–88 years old) (Fig. 1). Sixty-two of these patients had chronic liver disease or cirrhosis, of which 49 had a Child-Pugh score of 5, 9 had a score of 6, and 4 had a score of 7.

Ihara K., Onoda H., Tanabe M., Iida E., Ueda T., Kobayashi T., Higashi M., Nickel M.D., Imai H, & Ito K. (2023). Breath-hold High-resolution T1-weighted Gradient Echo Liver MR Imaging with Compressed Sensing Obtained during the Gadoxetic Acid-enhanced Hepatobiliary Phase: Image Quality and Lesion Visibility Compared with a Standard T1-weighted Sequence. Magnetic Resonance in Medical Sciences, 23(2), 146-152.

+ Open protocol

+ Expand

Gadoxetic Acid-Enhanced MRI Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Patients underwent gadoxetic acid-enhanced MRI at 3 T (Ingenia, Philips Healthcare) with a 32-channel torsocardiac phased-array coil. The interval between preoperative MRI and surgery was 33.0 ± 35.8 days (mean ± SD).
The gadoxetic acid-enhanced MRI comprised a multiphase dynamic study, in which the arterial-dominant, portal, late, and hepatobiliary phases were imaged. Fat-suppressed gradient-echo T1-weighted images with enhanced three-dimensional T1 high-resolution isotropic volume excitation (eTHRIVE) were obtained for each phase. The total amount of gadoxetic acid (EOB Primovist, Bayer, Osaka, Japan) based on the.patient's body weight (0.025 mmol/kg) was intravenously injected for 5 s, followed by a 20 ml physiological saline infusion with an automatic injector (Nemoto Kyorindo, Tokyo). Scanning of the hepatobiliary phase was performed 20 min after the injection of the contrast agent.

Fujita N., Ushijima Y., Itoyama M., Okamoto D., Ishimatsu K., Tabata K., Itoh S, & Ishigami K. (2024). Value of gadoxetic acid-enhanced MR imaging for preoperative prediction of future liver regeneration after hemihepatectomy. Japanese journal of radiology.

+ Open protocol

+ Expand

Evaluating Unresectable Colorectal Liver Metastases

Check if the same lab product or an alternative is used in the 5 most similar protocols

Between July 2010 and September 2015, 45 patients (mean age, 63 ± 10 years; 29 men [64%]) with CLMs were prospectively enrolled after NAC treatment. Everyone was examined by combined Gd-EOB-DTPA-enhanced (EOB Primovist; Bayer, Germany) and DW-MRI as well as IV contrast-enhanced 18 F-FDG PET/CT. Inclusion criteria were age older than 18 years and unresectable CLMs before NAC. Exclusion criteria were as follows: unresectable CLMs after NAC, contraindication to MRI (claustrophobia, renal failure with an estimated GFR <30 mL/min, pacemaker), contraindication to iodine contrast (renal failure with estimated GFR <30 mL/min, anaphylaxis). The resectability of the CLMs was established by consensus during multidisciplinary sessions including radiologists, oncologists, and surgeons. Of 45 included patients, 5 were considered unresectable after NAC (2 patients had peritoneal carcinomatosis, 2 had lung and bone metastases, 1 had a contraindication for anesthesia) and were excluded from the cohort. The remaining 40 patients were scheduled for resection of CLMs by laparotomy including an intraoperative US.
All patients proved written informed consent. The study was approved by the institutional review board and the ethics committee of the State of Vaud.

Dunet V., Halkic N., Prior J.O., Anaye A., Meuli R.A., Sempoux C., Denys A, & Schmidt S. (2017). Detection and Viability of Colorectal Liver Metastases After Neoadjuvant Chemotherapy: A Multiparametric PET/CT-MRI Study. Clinical nuclear medicine, 42(4).

+ Open protocol

+ Expand

Imaging Criteria for Uncomplicated Hepatic Cysts

Check if the same lab product or an alternative is used in the 5 most similar protocols

It is difficult to establish histopathologic findings as the reference standard for non-complicated hepatic cysts because they are benign. Therefore, our diagnosis of uncomplicated non-infectious hepatic cysts was based on imaging studies. An uncomplicated non-infectious hepatic cyst was diagnosed if all of the following criteria were met: (a) a homogenous hypo-attenuated lesion on unenhanced CT scans, (b) with no enhancement of the cyst wall and the cystic content on enhanced CT scans, (c) homogenous very low SI on T1-weighted MRI (T1-WI), (d) homogenous very high SI on T2-weighted MRI (T2-WI) [14] (link), [15] (link), (e) the absence of enhancement of the cyst wall or cystic content on dynamic gadoxetate disodium (EOB-Primovist, Bayer Yakuhin Ltd., Osaka, Japan)-enhanced MRI scans including the hepatobiliary phase, and (f) the lesion remained unchanged for more than 6 months to avoid the inclusion of patients with infectious or malignant hepatic cystic lesions [16] (link), [17] (link).

Nakamura Y., Higaki T., Akiyama Y., Fukumoto W., Kajiwara K., Kaichi Y., Honda Y., Komoto D., Tatsugami F., Iida M., Ohmoto T., Date S, & Awai K. (2016). Diffusion-weighted MR imaging of non-complicated hepatic cysts: Value of 3T computed diffusion-weighted imaging. European Journal of Radiology Open, 3, 138-144.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!